Selank (Nasal Spray)

Selank acts as a stabilized analogue of tuftsin, affecting GABAergic and serotonergic systems. Research data indicates anxiolytic action with a low sedative profile, although the data originates primarily from Russian studies.

• Nasal administration — no injection
• Approved in Russia as an anxiolytic
• Dosing: 250–500 mcg per application
• No reconstitution required

• Selank is approved in Russia as an anxiolytic drug in a nasal spray format (0.15%).
• It acts as a stabilized analogue of tuftsin, a natural immunopeptide.
• Nasal bioavailability is considered adequate based on clinical data, although the mechanism of central access remains under investigation.

• It is supplied as a ready-to-use nasal spray — no reconstitution is required.
• Self-preparation of nasal spray is not recommended.

• Refrigerator (2–8°C) after opening.
• Use within 14 days.

• 250–500 mcg per nostril, 3 times daily.
• Cycles of 10–14 days.

• Refrigerator (2–8°C).
• Protect from light.

• Not approved by the FDA or EMA.
• Clinical data is primarily from Russian studies.
• Self-preparation instructions are not provided.

Potential Benefits

• Anxiolytic action without drowsiness (research data)
• Potential enhancement of memory and learning
• Immunomodulatory properties (tuftsin analogue)

Potential Side Effects

• Mild nasal irritation
• Rare headache

1. Anxiolytic properties of Selank — Clinical trial — Clinical trial of the anxiolytic properties of Selank in nasal form
   Source →
2. Frontiers in Pharmacology (2016) — Selank & GABAergic Neurotransmission — Selank administration affects the expression of some genes involved in GABAergic neurotransmission
   Source →